*Keynote Speaker*
Current landscape and future opportunities in implementing human relevant models in pre-clinical drug development
Investigator, Complex In Vitro Models, Integrated Biological Platform Sciences (IBPS), PTS, GlaxoSmithKline
Dr. Claire Jeong is an Investigator in the Integrated Biological Platform Sciences (IBPS) group under Platform Technology and Sciences (PTS) Department at GlaxoSmithKline (GSK). She joined GSK in 2015 and is currently representing the Complex In Vitro Models (also as known as ‘Organoid Strategy’) team in IBPS/In Vitro-In Vivo Translation division. Prior to joining GSK, she was a GSK-funded research fellow at Wake Forest Institute of Regenerative Medicine (WFIRM) working with Dr. Anthony Atala and she worked on a collaborative GSK-WFIRM project: 3D bioprinted in vitro skin reconstruction for drug testing and wound healing. Claire received her BS degree in Biomedical Engineering from Johns Hopkins University, her MS/PhD in Biomedical Engineering specialized in Tissue Engineering such as biomaterials, 3D bioprinting, organs-on-chip, regenerative medicine from University of Michigan-Ann Arbor (under Dr. Scott Hollister’s guidance), and her immediate postdoctoral training in the same discipline at Duke University (under Dr. Lori Setton’s guidance).
